You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / CE

Specific Symptoms May Assist in Early Detection of Ovarian Cancer

  • Authors: News Author: Laurie Barclay, MD
    CME Author: Charles Vega, MD, FAAFP
  • CME / CE Released: 12/12/2006; Reviewed and Renewed: 12/12/2007
  • THIS ACTIVITY HAS EXPIRED
  • Valid for credit through: 12/12/2008
Start Activity


Target Audience and Goal Statement

This article is intended for primary care clinicians, obstetrician-gynecologists, and other specialists who care for women at risk for ovarian cancer.

The goal of this activity is to provide medical news to primary care clinicians and other healthcare professionals in order to enhance patient care.

Upon completion of this activity, participants will be able to:

  • Describe the epidemiology and prognosis of ovarian cancer.
  • List symptoms that are most predictive of ovarian cancer.


Disclosures

As an organization accredited by the ACCME, Medscape, LLC requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


Author(s)

  • Laurie Barclay, MD

    Laurie Barclay is a freelance reviewer and writer for Medscape.

    Disclosures

    Disclosure: Laurie Barclay, MD, has disclosed no relevant financial relationships.

CME Author(s)

  • Charles P Vega, MD

    Associate Professor; Residency Director, Department of Family Medicine, University of California, Irvine

    Disclosures

    Disclosure: Charles Vega, MD, FAAFP, has disclosed that he has received grants for educational activities from Pfizer.


Accreditation Statements

    For Physicians

  • Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Medscape, LLC designates this educational activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should only claim credit commensurate with the extent of their participation in the activity. Medscape Medical News has been reviewed and is acceptable for up to 200 Prescribed credits by the American Academy of Family Physicians. AAFP accreditation begins 09/01/06. Term of approval is for 1 year from this date. This activity is approved for 0.25 Prescribed credits. Credit may be claimed for 1 year from the date of this activity. AAFP credit is subject to change based on topic selection throughout the accreditation year.


    AAFP Accreditation Questions

    Contact This Provider

    For Nurses

  • This Activity is sponsored by Medscape Continuing Education Provider Unit.

    Medscape is an approved provider of continuing nursing education by the New York State Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.

    Approved for 0.25 contact hour(s) of continuing education for RNs and NPs; None of these credits is in the area of pharmacology.

    Provider Number: 6FDKKC-PRV-05

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. Medscape encourages you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 5 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

CME / CE

Specific Symptoms May Assist in Early Detection of Ovarian Cancer

Authors: News Author: Laurie Barclay, MD CME Author: Charles Vega, MD, FAAFPFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED

CME / CE Released: 12/12/2006; Reviewed and Renewed: 12/12/2007

Valid for credit through: 12/12/2008

processing....

December 12, 2006 — Early detection of ovarian cancer is possible through an evaluation of specific symptoms of recent onset and significant frequency, according to the results of a case-control study reported in the December 11 Early View issue of Cancer.

"Currently, screening for ovarian cancer is not recommended for the general population," write Barbara A. Goff, MD, of the University of Washington School of Medicine in Seattle, and colleagues. "Targeting women with specific symptoms for screening has been evaluated only recently, because it was believed that symptoms had limited specificity."

In this case-control study, 149 women with ovarian cancer, 255 women who were in a screening program, and 233 women who were referred for pelvic/abdominal ultrasound completed a survey of symptoms. Patients were randomized to an exploratory group or a confirmatory group, and symptom types, frequency, severity, and duration were compared between cases and controls. Using logistic regression, the investigators determined which factors independently predicted cancer in the exploratory group. These factors were then used to develop a symptom index, which was tested in the confirmatory group for sensitivity and specificity.

Symptoms that were associated significantly with ovarian cancer, when present for less than 1 year but occurring more than 12 days per month, were pelvic/abdominal pain, urinary urgency/frequency, increased abdominal size/bloating, and difficulty eating/feeling full. Logistic regression analysis revealed that symptoms that were associated independently with cancer were pelvic/abdominal pain (P < .001), increased abdominal size/bloating (P < .001), and difficulty eating/feeling full (P = .010).

A symptom index was considered positive if any of those 6 symptoms occurred more than 12 times per month but were present for less than 1 year. In the confirmatory sample, the symptom index was 56.7% sensitive for early-stage disease and 79.5% sensitive for advanced-stage disease. Specificity was 90% for women older than 50 years and 86.7% for women younger than 50 years.

Study limitations include possible recall bias.

"Specific symptoms in conjunction with their frequency and duration were useful in identifying women with ovarian cancer," the authors write. "A symptom index may be useful for identifying women who are at risk.... The current results suggest that women who complain of abdominal/pelvic pain, increased abdominal size/bloating, or difficulty eating/feeling full quickly that is of < 12 months' duration and occurs > 12 times per month should be evaluated for potential ovarian cancer."

The Marsha Rivkin Center for Ovarian Cancer Research (Seattle, Washington) and the National Institutes of Health/National Cancer Institute supported this study.

In an accompanying editorial, Sherry Salway Black, MBA, of the Ovarian Cancer National Alliance in Washington, DC, and colleagues note that recognition by the medical community of early-stage symptoms is relatively recent.

"The ultimate victory for survivors will be the identification of specific biomarkers for ovarian cancer that will enable development of a screening test," Ms. Black and colleagues write. "The symptom index has the potential to be a valuable tool — further research will determine to what extent.... Currently, awareness of these symptoms is our best hope for early detection."

Cancer. Published online December 11, 2006.

Clinical Context

Ovarian cancer will be diagnosed in approximately 21,000 women this year in the United States, making it the second most common gynecologic cancer. More than 70% of women are diagnosed at an advanced stage of the disease, which contributes to an average 5-year survival rate of only 20% to 30%. However, cure rates can be as high as 90% when patients receive treatment while the cancer is confined to the ovary.

Conventional medical wisdom dictates that symptoms of ovarian cancer may not present until the tumor has advanced past the early stages of growth. The authors of the current study examine whether certain symptoms might help suggest a diagnosis of ovarian cancer early in the disease process.

Study Highlights

  • Study participants were drawn from 1 of 3 groups: women undergoing surgery for pelvic masses, women presenting for pelvic ultrasound, and women participating in a screening study for ovarian cancer. Women completed a survey inquiring into the presence of 23 symptoms before they were aware of their diagnoses.
  • The main study outcome was a case-control comparison examining the presence of symptoms associated with ovarian cancer. This result was adjusted for the presence of depressive symptoms and age. The authors performed a regression analysis to determine the significance of symptoms related to ovarian cancer, and they also examined a group of significant symptoms for sensitivity and specificity in predicting ovarian cancer.
  • 149 women with ovarian cancer were compared with 458 controls. Among women with ovarian cancer, 55 had early-stage disease, 88 had late-stage disease, and 6 had an unknown stage of disease. Women with ovarian cancer were significantly older and had more symptoms compared with controls.
  • Pelvic and abdominal pain, urinary urgency and frequency, increased abdominal size and bloating, and early satiety were symptoms significantly associated with cases more often than controls.
  • The authors created a screening model for ovarian cancer that questioned the presence of pelvic and abdominal pain, increased abdominal size and bloating, and early satiety for less than 12 months. In this model, symptoms occurred more than 12 times per month. This model achieved a sensitivity and specificity of 66.7% and 90%, respectively, for detecting ovarian cancer among women older than 50 years. The respective sensitivity and specificity for women younger than 50 years were both 86.7%.
  • The sensitivity of the screening model for early-stage ovarian cancer was 56.7%, and the sensitivity increased to 79.5% when specifically examining late-stage cancer.
  • Applying the screening model to a study of a general population of women who previously completed the symptom questionnaire in a primary care clinic, the rate of at least 1 symptom present for less than 1 year and occurring more than 12 times per month was 2.6%. Rates of a positive screen result were 3.3% among women younger than 50 years old, and 1.4% among women at age 50 years or older.

Pearls for Practice

  • Ovarian cancer is the second most common gynecologic malignancy and is associated with 5-year survival rates between 20% and 30%. However, cure rates can be as high as 90% if the tumor is discovered in its earliest stages.
  • The current study found that pelvic and abdominal pain, increased abdominal size and bloating, and early satiety were symptomatic markers of ovarian cancer. When these symptoms are present for less than 12 months and occur more often than 12 times per month, they carry a specificity of up to 90% in the detection of ovarian cancer.

CME/CE Test

  • Print